Clinical Trial

A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia

Study acronym: Musashi
Recruiting
View on ClinicalTrials.gov →
Summary
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Protocol Amendment History 5 changes
critical Enrollment reopened 2026-08-01
notable Enrollment reduced: 2560 -> 2120 participants 2026-08-01
notable Trial sites expanded: 1 -> 23 locations 2026-08-01
notable Primary completion pushed: 2028-09-01 -> 2028-11-22 2026-08-01
minor Completion moved earlier: 2029-03-01 -> 2028-12-31 2026-08-01
Trial Details
NCT Number NCT07206472
Lead Sponsor Daiichi Sankyo
Conditions Primary Hypercholesterolaemia, Mixed Dyslipidemia
Enrollment 2,120 participants
Start Date 2026-03-03
Primary Completion 2028-11-22 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31